Dx/Rx: Prostate Cancer, Second Edition is a thoroughly revised and updated pocket-sized manual that details precise, up-to-date information for diagnosis and treatment of Prostate Cancer. Throughout the book, tables and figures summarize important clinical data and current professional society recommendations, while salient references direct readers to additional information.
Updates have been made to the Second Edition, including additional information on treatment options for both early and advanced prostate cancer, an improved staging section, including representative scans as well as new information on complications and para-neoplastic syndromes
Dx/Rx: Prostate Cancer features current, quick and concise information and is a must-have resource for instant access on the ward or in the clinic.
Table of Contents
Section 1 Introduction
Chapter 1 Basic Principles
Section 2 Clinical State: No Cancer Diagnosis
Chapter 2 The Diagnosis of Prostate Cancer
Chapter 3 Pathology of Prostate Cancer
Section 3 Clinical State: Localized Disease
Chapter 4 Staging and Risk Assessment
Chapter 5 Primary Management of Favorable- and Intermediate-Risk Prostate Cancer
Chapter 6 Management of High-Risk Prostate Cancer—Adjuvant and Neoadjuvant Strategies
Section 4 Clinical State: Rising PSA
Chapter 7 Biochemical Failure and Salvage Therapy
Section 5 Clinical States: Castrate and Noncastrate Metastatic Disease
Chapter 8 Hormone Therapy of Prostate Cancer
Chapter 9 Treatment of Castrate Resistant Prostate Cancer (CMPC)
Chapter 10 Selected Complications of Advanced Prostate Cancer
About the Authors
Lewis J. Kampel, MD-Memorial Sloan-Kettering Cancer Center - Joan and Sanford I. Weill Medical College of Cornell University
Dr. Kampel is a graduate of Rutgers University in New Brunswick, NJ, and the Georgetown University School of Medicine in Washington, DC. After training in Internal Medicine at the Cornell Cooperating Hospitals and NYU, he completed a fellowship in Medical Oncology at the Memorial Sloan-Kettering Cancer Center in NY. For the past 12 years he has been a member of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center with a special interest in prostate cancer and hemostatic disorders associated with the disease.